Neurocrine Biosciences (NBIX) – Analysts’ Weekly Ratings Changes

Posted by Francis Steltz on Aug 21st, 2026

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

8/13/2026 – Neurocrine Biosciences had its price target lowered by Morgan Stanley from $196.00 to $182.00. They now have an “equal weight” rating on the stock.
8/11/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
8/9/2026 – Neurocrine Biosciences was downgraded by Wall Street Zen from “buy” to “hold”.
8/4/2026 – Neurocrine Biosciences was downgraded by Zacks Research from “strong-buy” to “hold”.
8/3/2026 – Neurocrine Biosciences had its price target raised by Canaccord Genuity Group Inc. from $200.00 to $210.00. They now have a “buy” rating on the stock.
8/3/2026 – Neurocrine Biosciences had its price target raised by Truist Financial Corporation from $200.00 to $213.00. They now have a “buy” rating on the stock.
8/3/2026 – Neurocrine Biosciences had its price target raised by Wedbush from $185.00 to $194.00. They now have an “outperform” rating on the stock.
8/1/2026 – Neurocrine Biosciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
7/31/2026 – Neurocrine Biosciences had its price target raised by Citigroup Inc. from $246.00 to $249.00. They now have a “buy” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $195.00 to $198.00. They now have an “outperform” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $193.00 to $196.00. They now have an “equal weight” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by TD Cowen from $200.00 to $220.00. They now have a “buy” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Cantor Fitzgerald from $210.00 to $215.00. They now have an “overweight” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Piper Sandler from $207.00 to $210.00. They now have an “overweight” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Stifel Nicolaus from $188.00 to $215.00. They now have a “buy” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $200.00 to $222.00. They now have a “buy” rating on the stock.
7/31/2026 – Neurocrine Biosciences had its price target raised by Needham & Company LLC from $200.00 to $204.00. They now have a “buy” rating on the stock.
7/28/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
7/21/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $175.00 to $200.00. They now have a “buy” rating on the stock.
7/17/2026 – Neurocrine Biosciences had its price target raised by Wells Fargo & Company from $175.00 to $200.00. They now have an “overweight” rating on the stock.
7/13/2026 – Neurocrine Biosciences had its price target raised by Truist Financial Corporation from $155.00 to $200.00. They now have a “buy” rating on the stock.
7/13/2026 – Neurocrine Biosciences had its price target raised by BMO Capital Markets from $144.00 to $170.00. They now have a “market perform” rating on the stock.
7/10/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
7/7/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $183.00 to $195.00. They now have an “outperform” rating on the stock.
6/24/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
6/23/2026 – Neurocrine Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity

In related news, insider Ingrid Delaet sold 4,367 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $181.02, for a total value of $790,514.34. Following the completion of the sale, the insider owned 16,225 shares in the company, valued at $2,937,049.50. This trade represents a 21.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the sale, the director directly owned 1,588 shares in the company, valued at $289,031.88. This represents a 44.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,524 shares of company stock worth $21,668,924 in the last three months. 4.60% of the stock is currently owned by company insiders.

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Neurocrine Biosciences (NBIX) – Analysts’ Weekly Ratings Changes

Insider Activity

See Also

You might be interested in: